درباره این اپیزود
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have pronounced drug resistance and are believed to be the root cause of failure of many myeloma management therapies. We are talking to Dr William Matsui of Johns Hopkins University School of Medicine to learn about the latest research on multiple myeloma stem cells and their role in novel drug development to treat multiple myeloma.
انگلیسی
ایالات متحده آمریکا
رونوشت 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
جستجوی اپیزودهای گذشته
اپیزودهای قبلی CureTalks را جستجو کن.
قسمت های دیگر در این پادکست
Precision medicine is an emerging approach in cancer treatment and prevention. It is a shift away from a one-size-fits-all approach and requires sharing of information across research settings and community. Precision Medicine's central principle revolves around the ability to identify personal gen…
Intro call with Dr. Craig Hofmeister from Winship Cancer Institute.
ASCO 2019 concluded on June 4th and we are excited about Multiple Myeloma updates from the largest gathering of oncologists, researchers and health professionals. The myeloma panel is talking to Dr. Joseph Mikhael, Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Resear…
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Several types of immunotherapy are used to treat cancer. These treatments either re-engineer the immune cells or empower them to launch an attack on the cancer directly. Immunotherapy has led to remarkable resul…
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به CureTalks است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
